Clinical Trial News and Research

RSS

Prana's PBT2 receives FDA Orphan Drug designation for treatment of Huntington disease

Prana Biotechnology has today announced the US Food and Drug Administration has granted Orphan Drug designation to PBT2 for the treatment of Huntington Disease.

5 Sep 2014

Researchers to study effectiveness of atorvastatin in preventing heart problems in breast cancer patients

Wake Forest Baptist Medical Center has been awarded $4.4 million to conduct a multiple-site clinical trial testing the effectiveness of a statin drug in preventing cardiovascular events in women treated for breast cancer.

5 Sep 2014

Keytruda drug gets FDA approval for treatment of advanced melanoma

The U.S. Food and Drug Administration today approved a new immunotherapy drug to treat advanced melanoma, signaling a paradigm shift in the way the deadly skin cancer is treated.

5 Sep 2014

Ascend Biopharmaceuticals provides update on clinical trial program for lead immunotherapy products

Ascend Biopharmaceuticals, a Melbourne-based immunotherapy company, has released an update on the clinical trial pipeline for its lead immunotherapy products treating basal cell carcinoma (BCC) and breast cancer.

4 Sep 2014

Study shows 1 in 10 patients may not need surgery following heart attack

Researchers from the Golden Jubilee National Hospital and the University of Glasgow have reported a study that shows one in ten patients may not need cardiac intervention following a heart attack and in those that do need stents, the procedure can be targeted more effectively.

4 Sep 2014

Ludwig, CRI collaborate with VentiRx to conduct clinical trial with motolimod and immunotherapy agents

The nonprofits Ludwig Cancer Research (Ludwig) and the Cancer Research Institute (CRI) announced today an agreement with VentiRx Pharmaceuticals Inc., a clinical stage biopharmaceutical company, to conduct a clinical trial with motolimod (VTX-2337) combined with other immunotherapy agents available to Ludwig and CRI through other industry partnerships.

4 Sep 2014

Clinical trial to assess safety and efficacy of novel monoclonal antibody for CLL patients

Researchers at the University of California, San Diego School of Medicine, in partnership with the California Institute for Regenerative Medicine (CIRM) and Celgene Corporation, a New Jersey-based biopharmaceutical company, have launched a phase 1 human clinical trial to assess the safety and efficacy of a novel monoclonal antibody for patients with chronic lymphocytic leukemia (CLL).

4 Sep 2014

Pacific Edge signs agreement with SCPMG to evaluate Cxbladder User Program

Pacific Edge Ltd, a cancer diagnostics company, has signed an agreement with Southern California Permanente Medical Group (SCPMG) to research its User Program to evaluate its bladder cancer technology Cxbladder within the clinical settings of Kaiser Permanente's health care network.

3 Sep 2014

One-two punch designed to knock out most dangerous brain cancer

University of Michigan Health System doctors have started testing a unique new approach to fighting brain tumors -- one that delivers a one-two punch designed to knock out the most dangerous brain cancer.

3 Sep 2014

Infinity and AbbVie enter into global collaboration to develop and commercialize duvelisib

Infinity Pharmaceuticals, Inc. and AbbVie Inc. today announced that they have entered into a global collaboration to develop and commercialize duvelisib (IPI-145), Infinity's oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, for the treatment of patients with cancer.

3 Sep 2014

Clinical studies to treat unmet medical need post-transplantation

A class of biotechnology drugs called monoclonal antibodies is now being tested in clinical studies to treat an unmet medical need post-transplantation, called delayed graft function

3 Sep 2014

Novel polypill increases patient adherence to treatment following heart attack

New research shows a novel polypill increases patient adherence to treatment following a myocardial infarction (MI) or heart attack, according to new study results reported at the European Society of Cardiology's ESC Congress 2014 in Barcelona, Spain.

3 Sep 2014

Researchers create new drug to reduce inflammation of donor organ after transplantation

To reduce the number of discards and thus make more kidneys available, researchers and medical scientists from the European consortium MABSOT have created a new drug called OPN-305 to reduce inflammation of the donor organ after transplantation.

3 Sep 2014

ANP reports primary efficacy results from ATL1103 Phase II trial in patients with acromegaly

Antisense Therapeutics Limited is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening growth disorder, acromegaly.

2 Sep 2014

MEI Pharma completes patient enrollment in Pracinostat Phase II trial for treatment of MDS

MEI Pharma, Inc., an oncology company focused on the clinical development of novel therapies for cancer, announced today that it has completed enrollment in a randomized Phase II clinical trial of its lead investigational drug candidate Pracinostat in combination with azacitidine in patients with previously untreated intermediate-2 or high-risk myelodysplastic syndrome (MDS).

2 Sep 2014

Ampio updates phase III, multicenter, double-blind STEP study of Ampion for knee osteoarthritis

Ampio Pharmaceuticals, Inc. today announced an update on the phase III, multicenter, double-blind STEP study of Ampion™ for osteoarthritis of the knee.

2 Sep 2014

Soligenix announces promising preliminary results from study on ricin toxin vaccine

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today promising preliminary results from a preclinical study with its ricin toxin vaccine RiVax™, in a non-human primate (NHP) lethal aerosol exposure model.

2 Sep 2014

Concordia's subsidiary signs collaboration deal with Orphan Canada for PHOTOFRIN

Concordia Healthcare Corp., a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced that its subsidiary, Pinnacle Biologics, Inc., a biopharmaceutical research and development company specializing in rare diseases, has signed a collaboration agreement for PHOTOFRIN® with Orphan Canada, a Toronto-based specialty pharmaceutical company that in‐licenses therapies for rare disorders and specialty medicines within Canada.

2 Sep 2014

Thrombus aspiration for acute myocardial infarction does not reduce mortality

Thrombus aspiration for acute myocardial infarction (AMI) does not reduce mortality or other clinical endpoints long term, according to the awaited one-year follow-up results from the Thrombus Aspiration in ST- Elevation myocardial infarction in Scandinavia (TASTE) trial.

2 Sep 2014

Daily fruit consumption reduces risk of cardiovascular disease by up to 40%

Daily fruit consumption cuts the risk of cardiovascular disease (CVD) by up to 40%, according to research presented at ESC Congress today by Dr Huaidong Du from Oxford, UK.

2 Sep 2014

Clinical Trial News and Research

Prana's PBT2 receives FDA Orphan Drug designation for treatment of Huntington disease

Researchers to study effectiveness of atorvastatin in preventing heart problems in breast cancer patients

Keytruda drug gets FDA approval for treatment of advanced melanoma

Ascend Biopharmaceuticals provides update on clinical trial program for lead immunotherapy products

Study shows 1 in 10 patients may not need surgery following heart attack

Ludwig, CRI collaborate with VentiRx to conduct clinical trial with motolimod and immunotherapy agents

Clinical trial to assess safety and efficacy of novel monoclonal antibody for CLL patients

Pacific Edge signs agreement with SCPMG to evaluate Cxbladder User Program

One-two punch designed to knock out most dangerous brain cancer

Infinity and AbbVie enter into global collaboration to develop and commercialize duvelisib

Clinical studies to treat unmet medical need post-transplantation

Novel polypill increases patient adherence to treatment following heart attack

Researchers create new drug to reduce inflammation of donor organ after transplantation

ANP reports primary efficacy results from ATL1103 Phase II trial in patients with acromegaly

MEI Pharma completes patient enrollment in Pracinostat Phase II trial for treatment of MDS

Ampio updates phase III, multicenter, double-blind STEP study of Ampion for knee osteoarthritis

Soligenix announces promising preliminary results from study on ricin toxin vaccine

Concordia's subsidiary signs collaboration deal with Orphan Canada for PHOTOFRIN

Thrombus aspiration for acute myocardial infarction does not reduce mortality

Daily fruit consumption reduces risk of cardiovascular disease by up to 40%

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer